Samsung Biologics Strengthens Focus as a Pure-Play CDMO Through Spin-Off Samsung Biologics has successfully completed its spin-off from Samsung Bioepis. This strategic move reinforces its position as a leading pure-play CDMO, enhancing its focus and market strength.

Samsung Biologics Strengthens Focus as a Pure-Play CDMO Through Spin-Off #South_Korea #Samsung_Biologics #Incheon #CDMO #Samsung_Bioepis